Oops. Pfizer's CDK 4/6 blockbuster Ibrance flunks the OS mark for breast cancer
Just weeks after Novartis $NVS set out to burnish its prospects in breast cancer with promising progressive-free survival numbers for Kisqali and fulvestrant in treating patients with HR+/HER2- advanced breast cancer, rival Pfizer $PFE has some confessing to do today about its blockbuster market-leading duo using Ibrance.
Pfizer’s combo using fulvestrant failed to achieve statistical significance for overall survival in PALOMA-3, which will likely give the competition a serious leg up as they try to play catch-up. Ibrance is one of three key CDK 4/6 drugs on the market, including Kisqali and Eli Lilly’s $LLY Verzenio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.